Equities

IFR US ECM Pricings

 |  Robert Sherwood

Abony Acquisition I (Cayman Islands, SPAC) ─ $200m IPO. 20m units (Primary) at $10.00. BTIG. Nasdaq “AACOU”. Each unit comprises one share and one-third warrant. Lorne Abony/Leo Kofman. Defense technology and TMT. 24 months. 100% in trust.

Averin Capital Acquisition (US, SPAC) ─ $250m SPAC IPO. 25m units (Primary) at $10.00. DB. Nasdaq “ACAAU”. Each unit comprises one share and one-sixth warrant. Averin Capital. Not defined. 24 months. 100% in trust.

Compass Pathways (UK, biotech) ─ $150m FO. 18.8m ADRs (Primary) at $8.00 versus $8.45 last sale and $7.63 at launch. JEFF, TDC, CANT, STFL. Reverse inquiry. Structured with pre-funded warrants.

Eupraxia Pharmaceuticals (Canada, biotech) ─ $55m ABB. 7.9m shares (Primary) at $7.00 fixed price versus $8.16 last sale. CANT, LSCI. Upsized from $40m. Wall cross. Structured with pre-funded warrants.

Paloma Acquisition I (Cayman Islands, SPAC) ─ $150m IPO. 15m units (Primary) at $10.00. JEFF. Nasdaq “PALOU”. Each unit comprises one share and one-half warrant. Paloma Capital. Natural resources. 24 months. 100% in trust.

Topics
Equity Capital Americas North America United States ABBs and Block Trades Structured Equity Canada Initial Public Offerings (IPO) Marketed Follow-Ons US Dollar
Issuers
Compass Pathways PLC (CMPS.O) Eupraxia Pharmaceuticals Inc (EPRX.TO) Paloma Acquisition Corp I Abony Acquisition Corp I Averin Capital Acquisition Corp